

Principal Investigator

Department of Medical Data Science, Graduate School of Medicine, Osaka University

Professor Hideshi ISHII

Project Outline

■ Target Disease: refractory gastrointestinal cancers (pancreatic cancer, metastatic colorectal cancer)

■ Concept:

Simultaneous targeting of cancer stem cells and surrounding immune cells.

Cancer stem cells are buried within tumors, where they show resistance to conventional anti-cancer drugs and radiation therapy, which is the root cause of their refractory nature.

Surrounding immune cells produce an environment of tumor immunity, and, in a number of cancers, it can appear that immune checkpoint inhibitor therapy is already effective.

This is an academia-born project, being developed primarily at Osaka University, and is patented.

■ Market Trends:


The global market for cancer treatments in 2020 is projected to reach 500 billion dollars.

"Personalized strategies" are a KSF (Key Success Factor) in drug development for areas like refractory cancer, which require precision medicine.

■ Current Status:

At Osaka University we aim to develop new solutions to help conquer hard-to-treat cancers.

We are already patenting this technology, ramping up preclinical trials, and advancing physician-led clinical trials, and we are now in a phase that requires cooperation from drug manufacturers and venture companies.



Basic patent pending.

We are continuing development jointly, sharing information under contract.

We are proceeding with preclinical trials and physician-led clinical trials through a PMDA consultant.